New Alzheimer’s drug raises hopes along with questions
The FDA has approved Leqembi, the first disease treatment for early-stage Alzheimer’s disease and its precursor condition mild cognitive impairment. Medicare said it would pay for the treatment. Medical centers across the country are working to finalize policies and procedures for providing medications to patients, possibly by late summer or early fall. It’s a challenging … Read more